SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?


To: Larry Liebman who wrote (34)11/15/1999 2:41:00 PM
From: Biomaven  Read Replies (1) | Respond to of 824
 
Just in case anyone was as confused about this release as me:

Despite the "single dose" in the study title, IR confirmed this was indeed a dose-ranging study, but only one dose given to each patient in a group. The 8mg/kg was the top dose given.

The release seemed overblown to me, given that we are actually talking about the response of 3 people out of 6 here. Encouraging Phase I data, but no more than that.

I'm still holding for now.

Peter